Advanced Oncotherapy (AVO) is pleased to announce a newly established synergy collaboration between CERN and Application of Detectors and Accelerators to Medicine SA (“ADAM”).
A team of experts in accelerator and detector technology from CERN founded ADAM with Italian entrepreneur Dr Alberto Colussi in 2007. ADAM aims to capitalise on the know-how and infrastructure that CERN provides to build innovative accelerators for proton therapy and for conventional radiotherapy.
ADAM's research and development activities have focused on two main fields: the design and construction of compact linear accelerators for conventional radiotherapy, and of compact linear accelerators for proton therapy. The next phase of the collaboration, a newly established synergy between ADAM, CERN and AVO will complete the Proton Beam accelerator complex.
“For CERN the transfer of technology and know-how in the medical field is an important part of the impact of basic science on societal issues,” says CERN Director of Accelerators and Technology Steve Myers. “This partnership is a pragmatic way to share our competences and know-how with industrial partners who are able to bring this innovative medical solution to the market.”
Related Files: 2013_04_11 CERN ADAM announcement FINAL
©
April 11, 2013
January 13, 2013
TechPrecision Signs Agreement for Proton Beam Radiotherapy Systems
TechPrecision Corporation
1/7/2013
Ranor and WCMC Divisions to Produce Product Assemblies for Proton Beam Cancer Treatment Equipment
Center Valley, PA – January 7, 2013 – TechPrecision Corporation (OTC Bulletin Board: TPCS) (“TechPrecision” or “the Company”), an industry leading manufacturer providing engineering, precision large-scale machined, fabricated metal and electrical components for complete tested systems with customers in the alternative energy, cleantech, medical, nuclear, defense, aerospace and other commercial industries, today announced that it has signed a five-year agreement valued at more than $115 million to exclusively produce complete product assemblies for Proton Beam cancer treatment equipment in the U.S. and Asia.
“This agreement reflects the culmination of years of work with our customer to develop, perfect, and certify an efficient manufacturing process to produce a revolutionary system that provides a significant reduction in the size, cost and complexity of operating a proton therapy center,” said Mr. James Molinaro, CEO of TechPrecision Corporation. “This collaboration continues to be strategically beneficial to both organizations and now that the system has FDA clearance, pent-up demand indicates strong potential for this technology.”
The Proton Beam technology was recently cleared by the FDA (Food and Drug Administration). This agreement covers exclusive production for units that will be used in the U.S. and Asia and supplied from the Company’s Ranor and WCMC divisions. Under the terms of the agreement, the Company expects to begin shipping initial assemblies during Q1 FY2014 and continuing through Q4 FY2018. Individual purchase orders will be issued to TechPrecision for specific unit shipments within the terms of this agreement. These purchase orders will determine timing of shipments and revenue to TechPrecision, as well as minimum quantities for delivery. The Company has already successfully shipped five of these assemblies under a prior agreement.
“This agreement will benefit both our Ranor and WCMC divisions, as we will produce units to meet the market demand in the United States and Asia,” continued Mr. Molinaro. “As this agreement goes forward, cancer patients are the big winners as it signals a new, more cost-effective and less-invasive procedure that is now an available option to the medical community. An additional benefit of this agreement is the further diversification of TechPrecision’s revenue. Clearly, we are no longer reliant on the alternative energy sector, and medical shipments will become an increasingly important contributor to our top- and bottom-line results as this agreement transitions to purchase orders.”
About TechPrecision Corporation
TechPrecision Corporation, through its wholly owned subsidiaries, Ranor, Inc., and Wuxi Critical Mechanical Components Co., Ltd., globally manufactures large-scale, metal fabricated and machined precision components and equipment. These products are used in a variety of markets including: alternative energy (Solar and Wind), cleantech, medical, nuclear, defense, industrial, and aerospace to name a few. TechPrecision’s goal is to be an end-to-end global service provider to its customers by furnishing customized and integrated “turn-key” solutions for completed products requiring custom fabrication and machining, assembly, inspection and testing. To learn more about the Company, please visit the corporate website at http://www.techprecision.com. Information on the Company’s website or any other website does not constitute a part of this press release.
©
1/7/2013
Ranor and WCMC Divisions to Produce Product Assemblies for Proton Beam Cancer Treatment Equipment
Center Valley, PA – January 7, 2013 – TechPrecision Corporation (OTC Bulletin Board: TPCS) (“TechPrecision” or “the Company”), an industry leading manufacturer providing engineering, precision large-scale machined, fabricated metal and electrical components for complete tested systems with customers in the alternative energy, cleantech, medical, nuclear, defense, aerospace and other commercial industries, today announced that it has signed a five-year agreement valued at more than $115 million to exclusively produce complete product assemblies for Proton Beam cancer treatment equipment in the U.S. and Asia.
“This agreement reflects the culmination of years of work with our customer to develop, perfect, and certify an efficient manufacturing process to produce a revolutionary system that provides a significant reduction in the size, cost and complexity of operating a proton therapy center,” said Mr. James Molinaro, CEO of TechPrecision Corporation. “This collaboration continues to be strategically beneficial to both organizations and now that the system has FDA clearance, pent-up demand indicates strong potential for this technology.”
The Proton Beam technology was recently cleared by the FDA (Food and Drug Administration). This agreement covers exclusive production for units that will be used in the U.S. and Asia and supplied from the Company’s Ranor and WCMC divisions. Under the terms of the agreement, the Company expects to begin shipping initial assemblies during Q1 FY2014 and continuing through Q4 FY2018. Individual purchase orders will be issued to TechPrecision for specific unit shipments within the terms of this agreement. These purchase orders will determine timing of shipments and revenue to TechPrecision, as well as minimum quantities for delivery. The Company has already successfully shipped five of these assemblies under a prior agreement.
“This agreement will benefit both our Ranor and WCMC divisions, as we will produce units to meet the market demand in the United States and Asia,” continued Mr. Molinaro. “As this agreement goes forward, cancer patients are the big winners as it signals a new, more cost-effective and less-invasive procedure that is now an available option to the medical community. An additional benefit of this agreement is the further diversification of TechPrecision’s revenue. Clearly, we are no longer reliant on the alternative energy sector, and medical shipments will become an increasingly important contributor to our top- and bottom-line results as this agreement transitions to purchase orders.”
About TechPrecision Corporation
TechPrecision Corporation, through its wholly owned subsidiaries, Ranor, Inc., and Wuxi Critical Mechanical Components Co., Ltd., globally manufactures large-scale, metal fabricated and machined precision components and equipment. These products are used in a variety of markets including: alternative energy (Solar and Wind), cleantech, medical, nuclear, defense, industrial, and aerospace to name a few. TechPrecision’s goal is to be an end-to-end global service provider to its customers by furnishing customized and integrated “turn-key” solutions for completed products requiring custom fabrication and machining, assembly, inspection and testing. To learn more about the Company, please visit the corporate website at http://www.techprecision.com. Information on the Company’s website or any other website does not constitute a part of this press release.
©
December 20, 2012
EMMA promises better cancer therapy
University of Oxford
Source: STFC
10 Jan 12
The first results from a new type of particle accelerator suggest how smaller, cheaper therapy machines, which could revolutionise cancer treatment, could be built.
The prototype accelerator EMMA (Electron Model for Many Applications), which was constructed at the Science and Technology Facilities Council’s (STFC) Daresbury Laboratory, was designed by an international team including Oxford University scientists.
Current accelerators – used in medicine in conventional radiation therapy and X-ray machines as well as industry and fundamental scientific research – are limited by their size, complexity and cost.
EMMA’s technology is more compact, cost effective and operationally simpler, allowing the more widespread use of accelerators to tackle some of the most difficult problems facing society. The team report in Nature Physics the first experimental results from EMMA, confirming the proof of principle underlying its technology.
It is hoped that in the future this technology will allow hospitals to implement a newer and more effective form of beam therapy to help cure some of the most difficult cancers.
Professor Ken Peach of the John Adams Institute for Accelerator Science and the Oxford Martin School’s Particle Therapy Cancer Research Institute said: ‘This is a very exciting result – it is very rare these days to discover a new principle of particle acceleration, and this could lead to the development of novel or greatly improved applications of accelerators, for example in the treatment of some forms of cancer.’
EMMA’s ground-breaking concept is based on a ring of magnets which use their combined magnetic field simultaneously to steer and focus the electron beam around the machine. The strength of this magnetic field increases steeply as the beam spirals outwards while it is accelerated to 20 million electron volts around the ring. Due to the strength of the magnetic focussing, the displacement of the beam as it accelerates and spirals around the ring is much smaller than in any equivalent accelerator. As a result, EMMA’s ring of magnets is much more compact and it is easier to accelerate the beam.
The experience gained in the development and operation of EMMA's new technology will inform the design and eventual construction of a prototype proton/carbon ion accelerator for medical applications (PAMELA).
Engineered and constructed at the Science and Technology Facilities Council’s (STFC) Daresbury Laboratory, EMMA was designed by an international consortium of scientists as part of the CONFORM project, which includes the Universities of Manchester, Oxford, Surrey, Imperial, Brunel, Liverpool and Huddersfield, STFC, the Cockcroft and John Adams Institutes, as well as a number of international partners which include the Brookhaven National Laboratory and Fermilab in the US, and TRIUMF in Canada.
©
Source: STFC
10 Jan 12
The EMMA particle accelerator. Photo: STFC
The first results from a new type of particle accelerator suggest how smaller, cheaper therapy machines, which could revolutionise cancer treatment, could be built.
The prototype accelerator EMMA (Electron Model for Many Applications), which was constructed at the Science and Technology Facilities Council’s (STFC) Daresbury Laboratory, was designed by an international team including Oxford University scientists.
Current accelerators – used in medicine in conventional radiation therapy and X-ray machines as well as industry and fundamental scientific research – are limited by their size, complexity and cost.
EMMA’s technology is more compact, cost effective and operationally simpler, allowing the more widespread use of accelerators to tackle some of the most difficult problems facing society. The team report in Nature Physics the first experimental results from EMMA, confirming the proof of principle underlying its technology.
It is hoped that in the future this technology will allow hospitals to implement a newer and more effective form of beam therapy to help cure some of the most difficult cancers.
Professor Ken Peach of the John Adams Institute for Accelerator Science and the Oxford Martin School’s Particle Therapy Cancer Research Institute said: ‘This is a very exciting result – it is very rare these days to discover a new principle of particle acceleration, and this could lead to the development of novel or greatly improved applications of accelerators, for example in the treatment of some forms of cancer.’
EMMA’s ground-breaking concept is based on a ring of magnets which use their combined magnetic field simultaneously to steer and focus the electron beam around the machine. The strength of this magnetic field increases steeply as the beam spirals outwards while it is accelerated to 20 million electron volts around the ring. Due to the strength of the magnetic focussing, the displacement of the beam as it accelerates and spirals around the ring is much smaller than in any equivalent accelerator. As a result, EMMA’s ring of magnets is much more compact and it is easier to accelerate the beam.
The experience gained in the development and operation of EMMA's new technology will inform the design and eventual construction of a prototype proton/carbon ion accelerator for medical applications (PAMELA).
Engineered and constructed at the Science and Technology Facilities Council’s (STFC) Daresbury Laboratory, EMMA was designed by an international consortium of scientists as part of the CONFORM project, which includes the Universities of Manchester, Oxford, Surrey, Imperial, Brunel, Liverpool and Huddersfield, STFC, the Cockcroft and John Adams Institutes, as well as a number of international partners which include the Brookhaven National Laboratory and Fermilab in the US, and TRIUMF in Canada.
©
Subscribe to:
Posts (Atom)